PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
9.07%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.58%. Joel Greenblatt would investigate if growth quality matches quantity.
8.27%
Cost growth of 8.27% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
12.51%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.91%. Joel Greenblatt would investigate competitive advantages.
3.16%
Margin change of 3.16% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.99%
Other expenses change of 25.99% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
8.87%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 3.40%. Jim Chanos would check for waste.
8.37%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 3.11%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
11.18%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.33%. Jim Chanos would check for overinvestment.
21.31%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 1.39%. Joel Greenblatt would investigate advantages.
11.22%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 3.89%. Joel Greenblatt would investigate advantages.
26.60%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.91%. Joel Greenblatt would investigate advantages.
16.07%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 2.43%. Joel Greenblatt would investigate advantages.
-1.33%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
24.06%
Income change of 24.06% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
13.74%
Margin change of 13.74% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
17.04%
Tax expense change of 17.04% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
30.23%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.83%. Joel Greenblatt would investigate advantages.
19.40%
Net margin growth exceeding 1.5x Medical - Pharmaceuticals median of 0.61%. Joel Greenblatt would investigate advantages.
30.16%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.38%. Joel Greenblatt would investigate advantages.
30.16%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.70%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.